Savara’s IMPALA-2 Trial Success and FDA Submission Plan
Company Announcements

Savara’s IMPALA-2 Trial Success and FDA Submission Plan

Savara (SVRA) has issued an update.

Savara Inc. has announced significant success with its IMPALA-2 clinical trial, where the inhaled drug molgramostim demonstrated a meaningful improvement in lung function for autoimmune pulmonary alveolar proteinosis patients, meeting its primary endpoint at Week 24 and showing sustained effects at Week 48. Additional measures of health and physical activity also indicated benefits from the treatment. Well tolerated with a comparable rate of adverse events to the placebo, molgramostim is on track for a Biologics License Application submission to the FDA in early 2025, buoyed by multiple designations that could expedite its approval process.

Learn more about SVRA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlySavara management to meet virtually with Piper Sandler
Radhika Saraogi3 Best Stocks to Buy Now, 10/1/2024, According to Top Analysts 
TheFlySavara announces EAP for molgramostim for patients with aPAP
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App